Vascular factors, angiogenesis and biliary tract disease

Current Opinion in Gastroenterology

Volumn 26, Issue 3, 2010, Pages 246-250

  Glaser, Shannon S ^a   Gaudio, Eugenio ^b   Alpini, Gianfranco ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Angiogenesis; Biliary epithelial cells; Cholangiocytes; Cholestatic liver disease; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ANGIOGENESIS; BILE DUCT CARCINOMA; BILIARY CIRRHOSIS; BILIARY TRACT DISEASE; DISEASE COURSE; LIVER CYST; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

ANIMALS; BILIARY TRACT DISEASES; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 77951261269     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283369d19     Document Type: Review

References (37)

1. Strazzabosco M, Fabris L, Spirli C. Pathophysiology of cholangiopathies. J Clin Gastroenterol 2005; 39:S90-S102. (Pubitemid 40397022)
2. Alvaro D, Mancino MG, Glaser S, et al. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology 2007; 132:415-431. (Pubitemid 46108729)
3. Gaudio E, Pannarale L, Ripani M, et al. The hepatic microcirculation in experimental cirrhosis. A scanning electron microscopy study of microcorrosion casts. Scanning Microsc 1991; 5:495-502; discussion 502-1493
4. Gaudio E, Onori P, Pannarale L, Alvaro D. Hepatic microcirculation and peribiliary plexus in experimental biliary cirrhosis: a morphological study. Gastroenterology 1996; 111:1118-1124. (Pubitemid 26327616)
5. Nieves BJ, D'Amore PA, Bryan BA. The function of vascular endothelial growth factor. Biofactors 2009; 35:332-337.
6. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009; 21:154-165.
7. Gaudio E, Barbaro B, Alvaro D, et al. Administration of r-VEGF-A prevents hepatic artery ligation-induced bile duct damage in bile duct ligated rats. Am J Physiol Gastrointest Liver Physiol 2006; 291:G307-G317. (Pubitemid 44024691)
8. Gaudio E, Barbaro B, Alvaro D, et al. Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology 2006; 130:1270-1282.
9. Lazaridis KN, Strazzabosco M, LaRusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 2004; 127:1565-1577. (Pubitemid 39457780)
10. Rosmorduc O, Wendum D, Corpechot C, et al. Hepatocellular hypoxiainduced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am J Pathol 1999; 155:1065-1073. (Pubitemid 29488914)
11. Medina J, Sanz-Cameno P, Garcia-Buey L, et al. Evidence of angiogenesis in primary biliary cirrhosis: an immunohistochemical descriptive study. J Hepatol 2005; 42:124-131. (Pubitemid 40038910)
12. Mancinelli R, Onori P, Gaudio E, et al. Taurocholate feeding to bile duct ligated rats prevents caffeic acid-induced bile duct damage by changes in cholangiocyte VEGFexpression. Exp Biol Med (Maywood) 2009; 234:462-474.
13. Glaser S, Gaudio E, Francis H, et al. Bile acid feeding prevents hepatic artery ligation-induced bile duct injury in bile duct ligated rats (BDL) by PI3K/Aktdependent activation of cholangiocyte VEGF-A expression. Gastroenterology 2008; 134:S1590.
14. Friedman SL, Bansal MB. Reversal of hepatic fibrosis: fact or fantasy? Hepatology 2006; 43:S82-S88. (Pubitemid 43303972)
15. Omenetti A, Yang L, Li YX, et al. Hedgehog-mediated mesenchymal- epithelial interactions modulate hepatic response to bile duct ligation. Lab Invest 2007; 87:499-514. (Pubitemid 46633127)
16. Omenetti A, Syn WK, Jung Y, et al. Repair-related activation of hedgehog signaling promotes cholangiocyte chemokine production. Hepatology 2009; 50:518-527.
17. Witek RP, Yang L, Liu R, et al. Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells. Gastroenterology 2009; 136:320 e322-330 e322.
18. Taura K, De Minicis S, Seki E, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 2008; 135:1729-1738.
19. Tugues S, Fernandez-Varo G, Munoz-Luque J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007; 46:1919-1926.
20. Mejias M, Garcia-Pras E, Tiani C, et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009; 49:1245-1256.
21. Patsenker E, Popov Y, Stickel F, et al. Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 2009; 50:1501-1511.
22. Patsenker E, Popov Y, Stickel F, et al. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 2008; 135:660-670.
23. Patsenker E, Popov Y, Wiesner M, et al. Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. J Hepatol 2007; 46:878-887. (Pubitemid 46529034)
24. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis 2008; 12:131-150.
25. Alvaro D, Barbaro B, Franchitto A, et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol 2006; 169:877-888. (Pubitemid 44411954)
26. Tang D, Nagano H, Yamamoto H, et al. Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol Rep 2006; 15:525-532.
27. Mancino A, Mancino MG, Glaser S, et al. Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor. Dig Liver Dis 2009; 41:156-163.
28. Fava G, Demorrow S, Gaudio E, et al. Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression. Liver Int 2009; 29:1031-1042.
29. Francis H, Onori P, Gaudio E, et al. H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo. Mol Cancer Res 2009; 7:1704-1713.
30. Francis H, Franchitto A, Ueno Y, et al. H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ ERK1/2/ELK-1 pathway. Lab Invest 2007; 87:473-487. (Pubitemid 46633123)
31. Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 2008; 98:418-425. (Pubitemid 351161240)
32. Yoshikawa D, Ojima H, Kokubu A, et al. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer 2009; 100:1257-1266.
33. Brodsky KS, McWilliams RR, Amura CR, et al. Liver cyst cytokines promote endothelial cell proliferation and development. Exp Biol Med (Maywood) 2009; 234:1155-1165.
34. Fabris L, Cadamuro M, Fiorotto R, et al. Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology 2006; 43:1001-1012. (Pubitemid 43724625)
35. Spirli C, Okolicsanyi S, Fiorotto R, et al. ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice. Gastroenterology 2009. [Epub ahead of print].
36. Mack CL. The pathogenesis of biliary atresia: evidence for a virus-induced autoimmune disease. Semin Liver Dis 2007; 27:233-242.
37. Lee HC, Chang TY, Yeung CY, et al. Genetic variation in the vascular endothelial growth factor gene is associated with biliary atresia. J Clin Gastroenterol 2009 [Epub ahead of print].